TY - JOUR
T1 - The Non-Motor Symptoms Scale in Parkinson’s disease
T2 - Validation and use
AU - van Wamelen, Daniel J.
AU - Martinez-Martin, Pablo
AU - Weintraub, Daniel
AU - Schrag, Anette
AU - Antonini, Angelo
AU - Falup-Pecurariu, Cristian
AU - Odin, Per
AU - Ray Chaudhuri, Kallol
N1 - Funding Information:
The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.
Funding Information:
The development and worldwide validation of NMSS provided, for the first time, a roadmap for clinical quantification of the broad burden of NMS in PD patients. The scale has been validated with acceptable psychometric properties as a reliable and reproducible outcome measures. To date, over 100 original research studies have made use of the NMSS as an outcome measure, clearly demonstrating the high prevalence and burden of NMS in PD. Given the relevance of the NMSS and the identified shortcomings, a revised expanded version (the MDS‐NMS) was sponsored by the International Parkinson Disease and Movement Disorder Society and very recently was validated. It is likely that the MDS‐NMS would be used accompanying motor measures such as the MDS‐UPDRS in clinical trials. 40
Publisher Copyright:
© 2020 The Authors. Acta Neurologica Scandinavica published by John Wiley & Sons Ltd
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/1
Y1 - 2021/1
N2 - The Non-Motor Symptoms Scale (NMSS) was developed and validated in 2007 as the first instrument for the comprehensive assessment of a range of non-motor symptoms in Parkinson's disease (PD). Thirteen years have elapsed since its introduction and extensive international validation with good psychometric attributes has been carried out. Here, we review the validation data of the NMSS and its cross-validity with other scales, and describe the key evidence derived from use of the NMSS in clinical studies. To date, over 100 clinical studies and trials have made use of it as an outcome measure, showing consistent and strong correlations between NMSS burden and health-related quality of life measures. Moreover, the scale has shown to be capable of detecting longitudinal changes in non-motor symptoms, where studies have shown differential changes over time of several of the NMSS domains. The scale has become a key outcome in several randomized clinical trials. Highlighting the prevalence and importance of non-motor symptoms to quality of life in patients with PD, the development of NMSS has also been useful in signposting clinical and biomarker based research addressing non-motor symptoms in PD.
AB - The Non-Motor Symptoms Scale (NMSS) was developed and validated in 2007 as the first instrument for the comprehensive assessment of a range of non-motor symptoms in Parkinson's disease (PD). Thirteen years have elapsed since its introduction and extensive international validation with good psychometric attributes has been carried out. Here, we review the validation data of the NMSS and its cross-validity with other scales, and describe the key evidence derived from use of the NMSS in clinical studies. To date, over 100 clinical studies and trials have made use of it as an outcome measure, showing consistent and strong correlations between NMSS burden and health-related quality of life measures. Moreover, the scale has shown to be capable of detecting longitudinal changes in non-motor symptoms, where studies have shown differential changes over time of several of the NMSS domains. The scale has become a key outcome in several randomized clinical trials. Highlighting the prevalence and importance of non-motor symptoms to quality of life in patients with PD, the development of NMSS has also been useful in signposting clinical and biomarker based research addressing non-motor symptoms in PD.
UR - http://www.scopus.com/inward/record.url?scp=85091683240&partnerID=8YFLogxK
U2 - 10.1111/ane.13336
DO - 10.1111/ane.13336
M3 - Review article
C2 - 32813911
AN - SCOPUS:85091683240
SN - 0001-6314
VL - 143
SP - 3
EP - 12
JO - Acta Neurologica Scandinavica
JF - Acta Neurologica Scandinavica
IS - 1
ER -